Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 323 articles:
HTML format
Text format



Single Articles


    May 2017
  1. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Text format     Abstract available


  2. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Text format     Abstract available


  3. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Text format     Abstract available


  4. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Text format     Abstract available


  5. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Text format     Abstract available


  6. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Text format     Abstract available


  7. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Text format     Abstract available


  8. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Text format     Abstract available


  9. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Text format     Abstract available


  10. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Text format     Abstract available


  11. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Text format     Abstract available


  12. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Text format     Abstract available


  13. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Text format     Abstract available


  14. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Text format     Abstract available


  15. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Text format     Abstract available


  16. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Text format     Abstract available


  17. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Text format     Abstract available


  18. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Text format     Abstract available


  19. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Text format     Abstract available


  20. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Text format     Abstract available


  21. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Text format     Abstract available


    April 2017
  22. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed     Text format    


  23. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Text format     Abstract available


  24. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Text format     Abstract available


  25. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Text format     Abstract available


  26. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Text format     Abstract available


  27. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Text format     Abstract available


  28. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Text format     Abstract available


  29. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Text format     Abstract available


  30. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Text format     Abstract available


  31. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Text format     Abstract available


  32. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Text format     Abstract available


  33. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Text format     Abstract available


  34. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Text format     Abstract available


  35. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Text format     Abstract available


  36. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Text format     Abstract available


  37. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed     Text format    


  38. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Text format     Abstract available


  39. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Text format     Abstract available


    March 2017
  40. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Text format     Abstract available


  41. PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
    Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Mult Scler. 2017;23:483-486.
    PubMed     Text format     Abstract available


  42. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed     Text format    


  43. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed     Text format    


  44. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Text format     Abstract available


  45. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Text format     Abstract available


  46. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Text format     Abstract available


  47. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Text format     Abstract available


  48. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Text format     Abstract available


  49. WATTJES MP, Warnke C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.
    Mult Scler. 2017 Mar 1:1352458516685170. doi: 10.1177/1352458516685170.
    PubMed     Text format    


  50. YAP SM, McGuigan C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Mult Scler. 2017 Mar 1:1352458517697909. doi: 10.1177/1352458517697909.
    PubMed     Text format    


  51. ENZINGER C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
    Mult Scler. 2017 Mar 1:1352458516681505. doi: 10.1177/1352458516681505.
    PubMed     Text format    


  52. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Text format     Abstract available


  53. BEBO BF JR, Fox RJ, Lee K, Utz U, et al
    Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.
    Mult Scler. 2017 Mar 1:1352458517698250. doi: 10.1177/1352458517698250.
    PubMed     Text format     Abstract available


  54. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Text format     Abstract available


  55. ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
    Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
    PubMed     Text format     Abstract available


  56. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Text format     Abstract available


  57. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Text format     Abstract available


  58. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Text format     Abstract available


  59. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed     Text format    


  60. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed     Text format    


  61. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Text format     Abstract available


  62. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Text format     Abstract available


    February 2017
  63. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
    PubMed     Text format     Abstract available


  64. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of modifiable risk factors in the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
    PubMed     Text format     Abstract available


  65. PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
    Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
    PubMed     Text format     Abstract available


  66. CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
    Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Mult Scler. 2017;23:297-299.
    PubMed     Text format     Abstract available


  67. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed     Text format    


  68. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Text format     Abstract available


  69. BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
    Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
    PubMed     Text format     Abstract available


  70. MOTL RW, Cohen JA, Benedict R, Phillips G, et al
    Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
    PubMed     Text format     Abstract available


  71. BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
    Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
    PubMed     Text format     Abstract available


  72. FEYS P, Lamers I, Francis G, Benedict R, et al
    The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
    PubMed     Text format     Abstract available


  73. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed     Text format    


  74. SHOR N, Amador MD, Dormont D, Lubetzki C, et al
    Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
    Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
    PubMed     Text format     Abstract available


  75. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed     Text format    


  76. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Text format     Abstract available


  77. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Text format     Abstract available


  78. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Text format     Abstract available


  79. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Text format     Abstract available


  80. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Text format     Abstract available


  81. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Text format     Abstract available


  82. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Text format     Abstract available


  83. GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
    The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
    PubMed     Text format     Abstract available


  84. BARCELLOS LF, Bellesis KH, Shen L, Shao X, et al
    Remote assessment of verbal memory in MS patients using the California Verbal Learning Test.
    Mult Scler. 2017 Feb 1:1352458517694087. doi: 10.1177/1352458517694087.
    PubMed     Text format     Abstract available


  85. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Text format     Abstract available


  86. KOBELT G, Thompson A, Berg J, Gannedahl M, et al
    New insights into the burden and costs of multiple sclerosis in Europe.
    Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
    PubMed     Text format     Abstract available


  87. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Text format     Abstract available


  88. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Text format     Abstract available


  89. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Text format     Abstract available


  90. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Text format     Abstract available


    January 2017
  91. GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
    Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
    Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
    PubMed     Text format     Abstract available


  92. MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
    Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
    Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
    PubMed     Text format     Abstract available


  93. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Text format     Abstract available


  94. SUN H
    Temperature dependence of multiple sclerosis mortality rates in the United States.
    Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
    PubMed     Text format     Abstract available


  95. LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
    Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
    PubMed     Text format     Abstract available


  96. SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
    Similar familial risk in multiple sclerosis subgroups.
    Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
    PubMed     Text format     Abstract available


  97. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Text format     Abstract available


  98. MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
    The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
    PubMed     Text format     Abstract available


  99. BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
    Polyunsaturated fatty acids and the risk of multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
    PubMed     Text format     Abstract available


  100. GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
    Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
    PubMed     Text format     Abstract available


  101. MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
    Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
    PubMed     Text format     Abstract available


    December 2016
  102. MANOUCHEHRINIA A, Beiki O, Hillert J
    Clinical course of multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2016 Dec 12. pii: 1352458516681197.
    PubMed     Text format     Abstract available


  103. BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
    Breaking down the gut microbiome composition in multiple sclerosis.
    Mult Scler. 2016 Dec 12. pii: 1352458516682105.
    PubMed     Text format     Abstract available


  104. KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
    No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
    PubMed     Text format     Abstract available


  105. CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
    Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
    PubMed     Text format     Abstract available


  106. WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
    Infection-related health care utilization among people with and without multiple sclerosis.
    Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
    PubMed     Text format     Abstract available


  107. IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
    Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
    Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
    PubMed     Text format     Abstract available


  108. BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
    Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
    Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
    PubMed     Text format     Abstract available


  109. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed     Text format    


    November 2016
  110. GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
    Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Mult Scler. 2016 Nov 30. pii: 1352458516680749.
    PubMed     Text format     Abstract available


  111. HARRISON AM, das Nair R, Moss-Morris R
    Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
    Mult Scler. 2016 Nov 30. pii: 1352458516681862.
    PubMed     Text format     Abstract available


  112. SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
    Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
    Mult Scler. 2016 Nov 30. pii: 1352458516682103.
    PubMed     Text format     Abstract available


  113. DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
    Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
    Mult Scler. 2016 Nov 30. pii: 1352458516681196.
    PubMed     Text format     Abstract available


  114. DATTA G, Violante IR, Scott G, Zimmerman K, et al
    Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
    Mult Scler. 2016 Nov 30. pii: 1352458516681504.
    PubMed     Text format     Abstract available


  115. VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
    Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Mult Scler. 2016 Nov 29. pii: 1352458516681503.
    PubMed     Text format     Abstract available


  116. VENTURA RE, Antezana AO, Bacon T, Kister I, et al
    Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
    Mult Scler. 2016 Nov 29. pii: 1352458516679894.
    PubMed     Text format     Abstract available


  117. ROY S, Frndak S, Drake AS, Irwin L, et al
    Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516679036.
    PubMed     Text format     Abstract available


  118. VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
    Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516678934.
    PubMed     Text format     Abstract available


  119. ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
    Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516677589.
    PubMed     Text format     Abstract available


  120. ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
    Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677867.
    PubMed     Text format     Abstract available


  121. CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
    CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677591.
    PubMed     Text format     Abstract available


  122. SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
    The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
    Mult Scler. 2016 Nov 3. pii: 1352458516677592.
    PubMed     Text format     Abstract available


  123. MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
    Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
    Mult Scler. 2016 Nov 3. pii: 1352458516677590.
    PubMed     Text format     Abstract available


  124. CHATAWAY J
    Biotin in progressive multiple sclerosis: A new lead?
    Mult Scler. 2016;22:1640-1641.
    PubMed     Text format    


  125. GABILONDO I, Rilo O, Ojeda N, Pena J, et al
    The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
    Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
    PubMed     Text format     Abstract available


  126. CARUANA P, Lemmert K, Ribbons K, Lea R, et al
    Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
    Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
    PubMed     Text format     Abstract available


    October 2016
  127. PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
    Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2016 Oct 25. pii: 1352458516675750.
    PubMed     Text format     Abstract available


  128. BSTEH G, Feige J, Ehling R, Auer M, et al
    Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Mult Scler. 2016 Oct 20. pii: 1352458516675751.
    PubMed     Text format     Abstract available


  129. D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
    Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    Mult Scler. 2016 Oct 19. pii: 1352458516674567.
    PubMed     Text format     Abstract available


  130. KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
    Importance of early treatment initiation in the clinical course of multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516675039.
    PubMed     Text format     Abstract available


  131. PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
    CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516674566.
    PubMed     Text format     Abstract available


  132. RUANO L, Portaccio E, Goretti B, Niccolai C, et al
    Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
    Mult Scler. 2016 Oct 13. pii: 1352458516674367.
    PubMed     Text format     Abstract available


  133. WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
    The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
    Mult Scler. 2016 Oct 6. pii: 1352458516671818.
    PubMed     Text format     Abstract available


  134. AHMAD H, Taylor BV, van der Mei I, Colman S, et al
    The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
    Mult Scler. 2016 Oct 3. pii: 1352458516672014.
    PubMed     Text format     Abstract available


  135. LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
    The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
    Mult Scler. 2016;22:1607-1615.
    PubMed     Text format     Abstract available


  136. ARNETT P
    Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
    Mult Scler. 2016;22:1512-1513.
    PubMed     Text format    


    September 2016
  137. MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
    Employment, disability pension and income for children with parental multiple sclerosis.
    Mult Scler. 2016 Sep 28. pii: 1352458516672016.
    PubMed     Text format     Abstract available


  138. BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
    Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2016 Sep 28. pii: 1352458516671820.
    PubMed     Text format     Abstract available


  139. RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
    Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
    Mult Scler. 2016 Sep 28. pii: 1352458516671819.
    PubMed     Text format     Abstract available


  140. SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
    Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
    Mult Scler. 2016 Sep 27. pii: 1352458516670738.
    PubMed     Text format     Abstract available


  141. GAFSON A, Craner MJ, Matthews PM
    Personalised medicine for multiple sclerosis care.
    Mult Scler. 2016 Sep 26. pii: 1352458516672017.
    PubMed     Text format     Abstract available


  142. BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Mult Scler. 2016 Sep 23. pii: 1352458516671028.
    PubMed     Text format     Abstract available


  143. COLLIGAN E, Metzler A, Tiryaki E
    Shared decision-making in multiple sclerosis: A review.
    Mult Scler. 2016 Sep 23. pii: 1352458516671204.
    PubMed     Text format     Abstract available


  144. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed     Text format    


  145. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    Sick leave and disability pension before and after diagnosis of multiple sclerosis.
    Mult Scler. 2016 Sep 20. pii: 1352458516667567.
    PubMed     Text format     Abstract available


  146. CHOI IY, Lee P, Hughes AJ, Denney DR, et al
    Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Mult Scler. 2016 Sep 12. pii: 1352458516669441.
    PubMed     Text format     Abstract available


  147. ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
    Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Mult Scler. 2016 Sep 9. pii: 1352458516667564.
    PubMed     Text format     Abstract available


  148. HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
    Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Sep 9. pii: 1352458516669002.
    PubMed     Text format     Abstract available


  149. NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
    Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
    Mult Scler. 2016 Sep 9. pii: 1352458516666186.
    PubMed     Text format     Abstract available


  150. GRYTTEN N, Skar AB, Aarseth JH, Assmus J, et al
    The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.
    Mult Scler. 2016 Sep 6. pii: 1352458516667240.
    PubMed     Text format     Abstract available


  151. TOURBAH A, Lebrun-Frenay C, Edan G, Clanet M, et al
    MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
    Mult Scler. 2016 Sep 1. pii: 1352458516667568.
    PubMed     Text format     Abstract available


  152. MUKHOPADHYAY S, Fellows K, Browne RW, Khare P, et al
    Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.
    Mult Scler. 2016 Sep 1. pii: 1352458516666187.
    PubMed     Text format     Abstract available


    August 2016
  153. TROJAN DA, Cybulsky AV
    Drinking away fatigue in multiple sclerosis.
    Mult Scler. 2016 Aug 19. pii: 1352458516666337.
    PubMed     Text format    


  154. CINCOTTA MC, Engelhard MM, Stankey M, Goldman MD, et al
    Fatigue and fluid hydration status in multiple sclerosis: A hypothesis.
    Mult Scler. 2016 Aug 19. pii: 1352458516663854.
    PubMed     Text format     Abstract available


  155. MATHIAS A, Perriard G, Canales M, Soneson C, et al
    Increased ex vivo antigen presentation profile of B cells in multiple sclerosis.
    Mult Scler. 2016 Aug 8. pii: 1352458516664210.
    PubMed     Text format     Abstract available


  156. LANZA G, Ferri R, Bella R, Ferini-Strambi L, et al
    The impact of drugs for multiple sclerosis on sleep.
    Mult Scler. 2016 Aug 8. pii: 1352458516664034.
    PubMed     Text format     Abstract available


  157. KHAN O, Rieckmann P, Boyko A, Selmaj K, et al
    Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Mult Scler. 2016 Aug 8. pii: 1352458516664033.
    PubMed     Text format     Abstract available


  158. KIM HJ, Lee J
    Response to letter regarding article 'Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder'.
    Mult Scler. 2016 Aug 5. pii: 1352458516662730.
    PubMed     Text format    


  159. POMPA A, Morone G, Iosa M, Pace L, et al
    Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial.
    Mult Scler. 2016 Aug 2. pii: 1352458516663033.
    PubMed     Text format     Abstract available


  160. VERMERSCH P, Smets L, Gold R
    Conclusions: Calls to action for improving the life of MS patients and their families.
    Mult Scler. 2016;22.
    PubMed     Text format     Abstract available


  161. VERMERSCH P, Faller A, Czarnota-Szalkowska D, Meesen B, et al
    The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?
    Mult Scler. 2016;22.
    PubMed     Text format     Abstract available


  162. KALINCIK T, Kuhle J, Pucci E, Rojas JI, et al
    Data quality evaluation for observational multiple sclerosis registries.
    Mult Scler. 2016 Aug 1. pii: 1352458516662728.
    PubMed     Text format     Abstract available


  163. BOUTIERE C, Rey C, Zaaraoui W, Le Troter A, et al
    Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices.
    Mult Scler. 2016 Aug 1. pii: 1352458516661640.
    PubMed     Text format     Abstract available


  164. KHOURY SJ, Rochon J, Ding L, Byron M, et al
    ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Aug 1. pii: 1352458516662727.
    PubMed     Text format     Abstract available


  165. SCHREIBER K, Magyari M, Sellebjerg F, Iversen P, et al
    High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2016 Aug 1. pii: 1352458516661048.
    PubMed     Text format     Abstract available


  166. GROSS CC, Schulte-Mecklenbeck A, Hanning U, Posevitz-Fejfar A, et al
    Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.
    Mult Scler. 2016 Aug 1. pii: 1352458516662726.
    PubMed     Text format     Abstract available


    July 2016
  167. BUHLER U, Fleischer V, Luessi F, Rezk A, et al
    Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Mult Scler. 2016 Jul 19. pii: 1352458516658559.
    PubMed     Text format     Abstract available


  168. ONTANEDA D, Love TE
    Propensity methods for multiple sclerosis: The devil is in the details.
    Mult Scler. 2016 Jul 13. pii: 1352458516660390.
    PubMed     Text format    


  169. SBARDELLA E, Upadhyay N, Tona F, Prosperini L, et al
    Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.
    Mult Scler. 2016 Jul 13. pii: 1352458516657438.
    PubMed     Text format     Abstract available


    June 2016
  170. COFRE LIZAMA LE, Khan F, Lee PV, Galea MP, et al
    The use of laboratory gait analysis for understanding gait deterioration in people with multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658137.
    PubMed     Text format     Abstract available


  171. SOELBERG SORENSEN P, Sellebjerg F
    Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658560.
    PubMed     Text format    


  172. MCKAY KA, Tremlett H, Patten SB, Fisk JD, et al
    Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    Mult Scler. 2016 Jun 29. pii: 1352458516657440.
    PubMed     Text format     Abstract available


  173. VACCHI L, Rocca MA, Meani A, Rodegher M, et al
    Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.
    Mult Scler. 2016 Jun 28. pii: 1352458516656809.
    PubMed     Text format     Abstract available


  174. NISHIHARA H, Shimizu F, Kitagawa T, Yamanaka N, et al
    Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655217.
    PubMed     Text format     Abstract available


  175. SETHI V, Nair G, Absinta M, Sati P, et al
    Slowly eroding lesions in multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655403.
    PubMed     Text format     Abstract available


  176. ROSJO E, Lossius A, Abdelmagid N, Lindstrom JC, et al
    Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516654310.
    PubMed     Text format     Abstract available


  177. MENON S, Zhu F, Shirani A, Oger J, et al
    Disability progression in aggressive multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516653273.
    PubMed     Text format     Abstract available


  178. BURTON JM
    Response to "Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis" by Knippenberg et al.
    Mult Scler. 2016 Jun 14. pii: 1352458516652951.
    PubMed     Text format    


  179. KNIPPENBERG S, Smolders J, van den Maegdenbergh M, Porro G, et al
    Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis.
    Mult Scler. 2016 Jun 14. pii: 1352458516652950.
    PubMed     Text format    


  180. NAISMITH RT
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO.
    Mult Scler. 2016 Jun 8. pii: 1352458516644676.
    PubMed     Text format    


  181. MILLER AE
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.
    Mult Scler. 2016 Jun 8. pii: 1352458516649039.
    PubMed     Text format    


  182. GIOVANNONI G
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES.
    Mult Scler. 2016 Jun 8. pii: 1352458516650737.
    PubMed     Text format    


  183. BUSCARINU MC, Cerasoli B, Annibali V, Policano C, et al
    Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.
    Mult Scler. 2016 Jun 6. pii: 1352458516652498.
    PubMed     Text format     Abstract available


  184. CALABRESE M, Castellaro M, Bertoldo A, De Luca A, et al
    Epilepsy in multiple sclerosis: The role of temporal lobe damage.
    Mult Scler. 2016 Jun 3. pii: 1352458516651502.
    PubMed     Text format     Abstract available


    May 2016
  185. FLEISCHER V, Groger A, Koirala N, Droby A, et al
    Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651503.
    PubMed     Text format     Abstract available


  186. LEE H, Narayanan S, Brown RA, Chen JT, et al
    Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516650992.
    PubMed     Text format     Abstract available


  187. VISTBAKKA J, Elovaara I, Lehtimaki T, Hagman S, et al
    Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651141.
    PubMed     Text format     Abstract available


  188. CONWAY DS, Thompson NR, Cohen JA
    Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
    Mult Scler. 2016 May 26. pii: 1352458516650512.
    PubMed     Text format     Abstract available


  189. UHER T, Havrdova E, Sobisek L, Krasensky J, et al
    Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Mult Scler. 2016 May 26. pii: 1352458516650525.
    PubMed     Text format     Abstract available


  190. BARONCINI D, Ghezzi A, Annovazzi PO, Colombo B, et al
    Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Mult Scler. 2016 May 26. pii: 1352458516650736.
    PubMed     Text format     Abstract available


  191. OTERO-ROMERO S, Sastre-Garriga J, Comi G, Hartung HP, et al
    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Mult Scler. 2016 May 19. pii: 1352458516643600.
    PubMed     Text format     Abstract available


  192. LIU G, Zhang F, Jiang Y, Hu Y, et al
    Integrating genome-wide association studies and gene expression data highlights dysregulated multiple sclerosis risk pathways.
    Mult Scler. 2016 May 19. pii: 1352458516649038.
    PubMed     Text format     Abstract available


  193. GOLD R, Arnold DL, Bar-Or A, Hutchinson M, et al
    Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Mult Scler. 2016 May 19. pii: 1352458516649037.
    PubMed     Text format     Abstract available


  194. COSTA SL, Genova HM, DeLuca J, Chiaravalloti ND, et al
    Information processing speed in multiple sclerosis: Past, present, and future.
    Mult Scler. 2016 May 9. pii: 1352458516645869.
    PubMed     Text format     Abstract available


  195. BJORNEVIK K, Riise T, Benjaminsen E, Celius EG, et al
    Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
    Mult Scler. 2016 May 5. pii: 1352458516646863.
    PubMed     Text format     Abstract available


  196. MILLER AE
    Multiple sclerosis disease-modifying therapy and pregnancy.
    Mult Scler. 2016;22:715-6.
    PubMed     Text format    


    April 2016
  197. PAPATHEMELI D, Grafe R, Hildebrandt U, Zettl UK, et al
    Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler. 2016 Apr 26. pii: 1352458516645868.
    PubMed     Text format     Abstract available


  198. HUTCHINSON M
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary.
    Mult Scler. 2016 Apr 22. pii: 1352458516646466.
    PubMed     Text format    


  199. BRENNER R
    All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
    Mult Scler. 2016 Apr 22. pii: 1352458516642855.
    PubMed     Text format    


  200. BROWNLEE WJ, Ciccarelli O
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
    Mult Scler. 2016 Apr 22. pii: 1352458516636474.
    PubMed     Text format    


  201. LUDWIN SK, Rao VT, Moore CS, Antel JP, et al
    Astrocytes in multiple sclerosis.
    Mult Scler. 2016 Apr 19. pii: 1352458516643396.
    PubMed     Text format     Abstract available


  202. SASTRE-GARRIGA J
    Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected?
    Mult Scler. 2016 Apr 18. pii: 1352458516644677.
    PubMed     Text format     Abstract available


  203. VELDHUIJZEN VAN ZANTEN JJ, Pilutti LA, Duda JL, Motl RW, et al
    Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS?
    Mult Scler. 2016 Apr 12. pii: 1352458516644340.
    PubMed     Text format     Abstract available


  204. WESTERLIND H, Stawiarz L, Fink K, Hillert J, et al
    A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
    Mult Scler. 2016 Apr 12. pii: 1352458516643394.
    PubMed     Text format     Abstract available


  205. BEAUCHEMINA P, Carruthers R
    Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis.
    Mult Scler. 2016 Apr 11. pii: 1352458516643398.
    PubMed     Text format    


  206. KOCH-HENRIKSEN N, Magyari M, Sellebjerg F, Soelberg Sorensen P, et al
    A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Mult Scler. 2016 Apr 7. pii: 1352458516643393.
    PubMed     Text format     Abstract available


  207. STEWART T, Spelman T, Havrdova E, Horakova D, et al
    Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Mult Scler. 2016 Apr 7. pii: 1352458516643392.
    PubMed     Text format     Abstract available


  208. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2016 Apr 7. pii: 1352458516644058.
    PubMed     Text format     Abstract available


  209. UHER T, Vaneckova M, Sobisek L, Tyblova M, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Mult Scler. 2016 Apr 6. pii: 1352458516642314.
    PubMed     Text format     Abstract available


  210. MATOULA T, Nikolaou V, Marinos L, Katsavos S, et al
    Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
    Mult Scler. 2016 Apr 6. pii: 1352458516642032.
    PubMed     Text format    


  211. HARDY TA, Tobin WO, Lucchinetti CF
    Exploring the overlap between multiple sclerosis, tumefactive demyelination and Balo's concentric sclerosis.
    Mult Scler. 2016 Apr 1. pii: 1352458516641776.
    PubMed     Text format     Abstract available


  212. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue? Response to Feinstein.
    Mult Scler. 2016;22:575-6.
    PubMed     Text format    


  213. RACCA V, Di Rienzo M, Cavarretta R, Toccafondi A, et al
    Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Mult Scler. 2016;22:708-9.
    PubMed     Text format    


  214. MODVIG S, Degn M, Sander B, Horwitz H, et al
    Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
    Mult Scler. 2016;22:590-8.
    PubMed     Text format     Abstract available


  215. HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
    Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
    Mult Scler. 2016;22:649-58.
    PubMed     Text format     Abstract available


  216. FUJITA-NAKATA M, Tomioka R, Tanaka K, Nakanishi M, et al
    Intractable cough as characteristic symptom of neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016;22:576-7.
    PubMed     Text format    


  217. RADAELLI M, Moiola L, Sangalli F, Esposito F, et al
    Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
    Mult Scler. 2016;22:511-9.
    PubMed     Text format     Abstract available


  218. NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
    Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Mult Scler. 2016;22:483-93.
    PubMed     Text format     Abstract available


    March 2016
  219. PATEL VP, Zambrana A, Walker LA, Herrmann N, et al
    Distraction adds to the cognitive burden in multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641208.
    PubMed     Text format     Abstract available


  220. STROHM T, Chaudhry B, Willis MA, Shook S, et al
    Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641774.
    PubMed     Text format     Abstract available


  221. CADAVID D, Cohen JA, Freedman MS, Goldman MD, et al
    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Mar 22. pii: 1352458516638941.
    PubMed     Text format     Abstract available


  222. NOVAKOVA L, Axelsson M, Khademi M, Zetterberg H, et al
    Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Mult Scler. 2016 Mar 21. pii: 1352458516639384.
    PubMed     Text format     Abstract available


  223. MIDAGLIA L, Juega Marino JM, Sastre-Garriga J, Rovira A, et al
    An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.
    Mult Scler. 2016 Mar 18. pii: 1352458516638557.
    PubMed     Text format     Abstract available


  224. HILZ MJ
    Cardiac stunning as first manifestation of multiple sclerosis: A case report reminding us not to overlook cardiovascular autonomic dysfunction in multiple sclerosis.
    Mult Scler. 2016 Mar 18. pii: 1352458516638559.
    PubMed     Text format     Abstract available


  225. BECKER J, Rolfs A, Karabul N, Berlit P, et al
    D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic.
    Mult Scler. 2016 Mar 18. pii: 1352458516638747.
    PubMed     Text format     Abstract available


  226. PETRACCA M, Cordano C, Cellerino M, Button J, et al
    Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?
    Mult Scler. 2016 Mar 18. pii: 1352458516637679.
    PubMed     Text format     Abstract available


  227. ALBOR C, du Sautoy T, Kali Vanan N, Turner BP, et al
    Ethnicity and prevalence of multiple sclerosis in east London.
    Mult Scler. 2016 Mar 17. pii: 1352458516638746.
    PubMed     Text format     Abstract available


  228. OBERMANN M, Ruck T, Pfeuffer S, Baum J, et al
    Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Mar 15. pii: 1352458516638558.
    PubMed     Text format     Abstract available


  229. ZINGER A, Latham SL, Combes V, Byrne S, et al
    Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Mult Scler. 2016 Mar 1. pii: 1352458516636959.
    PubMed     Text format     Abstract available


  230. BEVER CT JR, Wallin MT
    Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
    Mult Scler. 2016;22:267-8.
    PubMed     Text format    


  231. ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
    Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
    Mult Scler. 2016;22:269-78.
    PubMed     Text format     Abstract available


  232. COBO-CALVO A, Sepulveda M, Bernard-Valnet R, Ruiz A, et al
    Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.
    Mult Scler. 2016;22:312-9.
    PubMed     Text format     Abstract available


  233. PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
    Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Mult Scler. 2016;22:302-11.
    PubMed     Text format     Abstract available


  234. MAKHANI N, Banwell B, Tellier R, Yea C, et al
    Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
    Mult Scler. 2016;22:385-8.
    PubMed     Text format     Abstract available


  235. VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
    Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Mult Scler. 2016;22:389-92.
    PubMed     Text format     Abstract available


  236. JEONG IH, Park B, Kim SH, Hyun JW, et al
    Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.
    Mult Scler. 2016;22:329-39.
    PubMed     Text format     Abstract available


    February 2016
  237. THIEL S, Langer-Gould A, Rockhoff M, Haghikia A, et al
    Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Mult Scler. 2016 Feb 26. pii: 1352458516634872.
    PubMed     Text format     Abstract available


  238. D'AMICO E, Leone C, Hayrettin T, Patti F, et al
    Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.
    Mult Scler. 2016 Feb 26. pii: 1352458516632066.
    PubMed     Text format     Abstract available


  239. KIM SH, Kwak K, Jeong IH, Hyun JW, et al
    Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516636246.
    PubMed     Text format     Abstract available


  240. FIEST KM, Marrie RA, Jette N, Bennett DA, et al
    The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516634873.
    PubMed     Text format     Abstract available


  241. SUMOWSKI JF, Rocca MA, Leavitt VM, Riccitelli G, et al
    Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516630822.
    PubMed     Text format     Abstract available


  242. WANG Y, Bos SD, Harbo HF, Thompson WK, et al
    Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors.
    Mult Scler. 2016 Feb 26. pii: 1352458516635873.
    PubMed     Text format     Abstract available


  243. JEONG IH, Choi JY, Kim SH, Hyun JW, et al
    Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Feb 26. pii: 1352458516636247.
    PubMed     Text format     Abstract available


  244. CAVALLARI M, Palotai M, Glanz BI, Egorova S, et al
    Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Feb 26. pii: 1352458516635874.
    PubMed     Text format     Abstract available


  245. RAZAZ N, Tremlett H, Marrie RA, Joseph KS, et al
    Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children.
    Mult Scler. 2016 Feb 22. pii: 1352458516631037.
    PubMed     Text format     Abstract available


  246. JIANG H, Delgado S, Tan J, Liu C, et al
    Impaired retinal microcirculation in multiple sclerosis.
    Mult Scler. 2016 Feb 22. pii: 1352458516631035.
    PubMed     Text format     Abstract available


  247. SANAI SA, Saini V, Benedict RH, Zivadinov R, et al
    Aging and multiple sclerosis.
    Mult Scler. 2016 Feb 19. pii: 1352458516634871.
    PubMed     Text format     Abstract available


  248. PHE V, Pakzad M, Curtis C, Porter B, et al
    Urinary tract infections in multiple sclerosis.
    Mult Scler. 2016 Feb 18. pii: 1352458516633903.
    PubMed     Text format     Abstract available


  249. DECKER Y, Schomburg R, Nemeth E, Vitkin A, et al
    Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients.
    Mult Scler. 2016 Feb 16. pii: 1352458516631036.
    PubMed     Text format     Abstract available


  250. MOKKINK LB, Galindo-Garre F, Uitdehaag BM
    Evaluation of the Multiple Sclerosis Walking Scale-12 (MSWS-12) in a Dutch sample: Application of item response theory.
    Mult Scler. 2016 Feb 12. pii: 1352458516630821.
    PubMed     Text format     Abstract available


  251. SCALFARI A, Lederer C, Daumer M, Nicholas R, et al
    The relationship of age with the clinical phenotype in multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516630396.
    PubMed     Text format     Abstract available


  252. JARIUS S, Metz I, Konig FB, Ruprecht K, et al
    Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
    Mult Scler. 2016 Feb 11. pii: 1352458515622986.
    PubMed     Text format     Abstract available


  253. PASTO L, Portaccio E, Goretti B, Ghezzi A, et al
    The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516629559.
    PubMed     Text format     Abstract available


  254. PAKPOOR J, Wotton CJ, Schmierer K, Giovannoni G, et al
    Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
    Mult Scler. 2016 Feb 8. pii: 1352458515627205.
    PubMed     Text format     Abstract available


  255. BISECCO A, Caiazzo G, d'Ambrosio A, Sacco R, et al
    Fatigue in multiple sclerosis: The contribution of occult white matter damage.
    Mult Scler. 2016 Feb 4. pii: 1352458516628331.
    PubMed     Text format     Abstract available


  256. PRAVATA E, Zecca C, Sestieri C, Caulo M, et al
    Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue.
    Mult Scler. 2016 Feb 4. pii: 1352458515625806.
    PubMed     Text format     Abstract available


  257. FAIVRE A, Robinet E, Guye M, Rousseau C, et al
    Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study.
    Mult Scler. 2016 Feb 2. pii: 1352458516628657.
    PubMed     Text format     Abstract available


  258. TAYLOR BV
    Modeling the course and outcomes of multiple sclerosis is statistical twaddle-Yes.
    Mult Scler. 2016;22:140-2.
    PubMed     Text format    


  259. BERGAMASCHI R, Montomoli C
    Modeling the course and outcomes of MS is statistical twaddle--No.
    Mult Scler. 2016;22:142-4.
    PubMed     Text format    


  260. FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
    Clinical and MRI phenotype of children with MOG antibodies.
    Mult Scler. 2016;22:174-84.
    PubMed     Text format     Abstract available


  261. HUPPERTS R, Lycke J, Short C, Gasperini C, et al
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Mult Scler. 2016;22:212-21.
    PubMed     Text format     Abstract available


  262. ABBOUD H, Petrak A, Mealy M, Sasidharan S, et al
    Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
    Mult Scler. 2016;22:185-92.
    PubMed     Text format     Abstract available


    January 2016
  263. LAULE C, Yung A, Pavolva V, Bohnet B, et al
    High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report.
    Mult Scler. 2016 Jan 27. pii: 1352458515624559.
    PubMed     Text format     Abstract available


  264. ZHOU Y, Zhu G, Charlesworth JC, Simpson S Jr, et al
    Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
    Mult Scler. 2016 Jan 27. pii: 1352458515626598.
    PubMed     Text format     Abstract available


  265. BEHRENS JR, Mertens S, Kruger T, Grobelny A, et al
    Validity of visual perceptive computing for static posturography in patients with multiple sclerosis.
    Mult Scler. 2016 Jan 26. pii: 1352458515625807.
    PubMed     Text format     Abstract available


  266. GEORGE IC, Sati P, Absinta M, Cortese IC, et al
    Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis.
    Mult Scler. 2016 Jan 14. pii: 1352458515624975.
    PubMed     Text format     Abstract available


  267. ZORNER B, Filli L, Reuter K, Kapitza S, et al
    Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Mult Scler. 2016 Jan 13. pii: 1352458515622695.
    PubMed     Text format     Abstract available


  268. KHALIL M, Renner A, Langkammer C, Enzinger C, et al
    Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Mult Scler. 2016 Jan 13. pii: 1352458515624560.
    PubMed     Text format     Abstract available


  269. OHRFELT A, Axelsson M, Malmestrom C, Novakova L, et al
    Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Mult Scler. 2016 Jan 11. pii: 1352458515624558.
    PubMed     Text format     Abstract available


  270. PANDIT L, Ban M, Beecham AH, McCauley JL, et al
    European multiple sclerosis risk variants in the south Asian population.
    Mult Scler. 2016 Jan 11. pii: 1352458515624270.
    PubMed     Text format     Abstract available


  271. BHARGAVA P, Calabresi PA
    Metabolomics in multiple sclerosis.
    Mult Scler. 2016 Jan 11. pii: 1352458515622827.
    PubMed     Text format     Abstract available


  272. HOJJAT SP, Cantrell CG, Vitorino R, Feinstein A, et al
    Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Jan 11. pii: 1352458515622696.
    PubMed     Text format     Abstract available


  273. NIELSEN NM, Harpsoe MC, Simonsen J, Stenager E, et al
    Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.
    Mult Scler. 2016 Jan 8. pii: 1352458515621623.
    PubMed     Text format     Abstract available


  274. HASSELMANN H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, et al
    Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression.
    Mult Scler. 2016 Jan 8. pii: 1352458515622826.
    PubMed     Text format     Abstract available


  275. COMABELLA M
    Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled - MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016 Jan 7. pii: 1352458515623863.
    PubMed     Text format     Abstract available


  276. MEIJER KA, Muhlert N, Cercignani M, Sethi V, et al
    White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515622694.
    PubMed     Text format     Abstract available


  277. MORI F, Nistico R, Nicoletti CG, Zagaglia S, et al
    RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515621796.
    PubMed     Text format     Abstract available


  278. SASTRE-GARRIGA J, Wiendl H
    Highlights from the 31st ECTRIMS congress - Barcelona 2015.
    Mult Scler. 2016;22:7-10.
    PubMed     Text format    


  279. REINGOLD SC, Lublin FD
    William Austin Sibley, MD (1925-2015).
    Mult Scler. 2016;22:11-2.
    PubMed     Text format    


  280. FREEDMAN MS
    Are we in need of NEDA?
    Mult Scler. 2016;22:5-6.
    PubMed     Text format    


  281. ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
    Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
    Mult Scler. 2016;22:125-6.
    PubMed     Text format    


    December 2015
  282. RAZAZ N, Joseph KS, Boyce WT, Guhn M, et al
    Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health.
    Mult Scler. 2015 Dec 18. pii: 1352458515621624.
    PubMed     Text format     Abstract available


  283. JONKMAN LE, Fleysher L, Steenwijk MD, Koeleman JA, et al
    Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515620499.
    PubMed     Text format     Abstract available


  284. CONTE A, Li Voti P, Pontecorvo S, Quartuccio ME, et al
    Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515619780.
    PubMed     Text format     Abstract available


  285. STRAUDI S, Fanciullacci C, Martinuzzi C, Pavarelli C, et al
    The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2015 Dec 10. pii: 1352458515620933.
    PubMed     Text format     Abstract available


  286. MISTRY N, Abdel-Fahim R, Samaraweera A, Mougin O, et al
    Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.
    Mult Scler. 2015 Dec 10. pii: 1352458515616700.
    PubMed     Text format     Abstract available


    November 2015
  287. SCHEEPE JR, Wong YY, van Pelt ED, Ketelslegers IA, et al
    Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis.
    Mult Scler. 2015 Nov 20. pii: 1352458515618541.
    PubMed     Text format     Abstract available


  288. KAPPOS L, De Stefano N, Freedman MS, Cree BA, et al
    Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Nov 19. pii: 1352458515616701.
    PubMed     Text format     Abstract available


  289. STEENWIJK MD, Vrenken H, Jonkman LE, Daams M, et al
    High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis.
    Mult Scler. 2015 Nov 12. pii: 1352458515615953.
    PubMed     Text format     Abstract available


  290. FOK A, Williams T, McLean CA, Butler E, et al
    Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515618020.
    PubMed     Text format     Abstract available


  291. WATTJES MP, Wijburg MT, Vennegoor A, Witte BI, et al
    Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515615225.
    PubMed     Text format     Abstract available


  292. YAMASAKI R, Matsushita T, Fukazawa T, Yokoyama K, et al
    Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Mult Scler. 2015 Nov 12. pii: 1352458515617248.
    PubMed     Text format     Abstract available


    May 2015
  293. LULU S, Graves J, Waubant E
    Menarche increases relapse risk in pediatric multiple sclerosis.
    Mult Scler. 2015 May 6. pii: 1352458515581873.
    PubMed     Text format     Abstract available


  294. GREENBERG BM
    Placebo studies should not be undertaken in NMO--No.
    Mult Scler. 2015;21:691-3.
    PubMed     Text format    


  295. WEINSHENKER BG
    Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary.
    Mult Scler. 2015;21:693-4.
    PubMed     Text format    


  296. PALACE J
    Placebo studies should not be undertaken in NMO--Yes.
    Mult Scler. 2015;21:689-91.
    PubMed     Text format    


  297. IORIO R, Rindi G, Erra C, Damato V, et al
    Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
    Mult Scler. 2015;21:791-4.
    PubMed     Text format     Abstract available


  298. LONGBRAKE EE, Cross AH
    Dimethyl fumarate associated lymphopenia in clinical practice.
    Mult Scler. 2015;21:796-7.
    PubMed     Text format    


  299. SASTRE-GARRIGA J, Tur C, Pareto D, Vidal-Jordana A, et al
    Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Mult Scler. 2015;21:749-56.
    PubMed     Text format     Abstract available


  300. VIDAL-JORDANA A, Tintore M, Tur C, Perez-Miralles F, et al
    Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Mult Scler. 2015;21:780-5.
    PubMed     Text format     Abstract available


  301. HYUN JW, Kim SH, Huh SY, Kim W, et al
    Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
    Mult Scler. 2015;21:710-7.
    PubMed     Text format     Abstract available


  302. COMI G, Gold R, Dahlke F, Sinha A, et al
    Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Mult Scler. 2015;21:786-90.
    PubMed     Text format     Abstract available


    April 2015
  303. MUSELLA A, Mandolesi G, Mori F, Gentile A, et al
    Linking synaptopathy and gray matter damage in multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515581875.
    PubMed     Text format    


  304. SINDIC C, Edan G
    Richard E Gonsette (1929-2014).
    Mult Scler. 2015;21:540.
    PubMed     Text format    


  305. TANAKA M, Kinoshita M, Tanaka K
    Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders.
    Mult Scler. 2015;21:669.
    PubMed     Text format    


  306. PEAUREAUX D, Pignolet B, Biotti D, Bucciarelli F, et al
    Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Mult Scler. 2015;21:671-2.
    PubMed     Text format    


  307. IKEDA K, Kiyota N, Kuroda H, Sato DK, et al
    Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.
    Mult Scler. 2015;21:656-9.
    PubMed     Text format     Abstract available


  308. PESCHL P, Reindl M, Schanda K, Sospedra M, et al
    Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells.
    Mult Scler. 2015;21:651-5.
    PubMed     Text format     Abstract available


  309. ELLIS R, Brown S, Boggild M
    Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Mult Scler. 2015;21:642-5.
    PubMed     Text format     Abstract available


  310. ARRAMBIDE G, Tur C, Montalban X
    Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.
    Mult Scler. 2015;21:660-1.
    PubMed     Text format    


  311. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue?
    Mult Scler. 2015;21:376-81.
    PubMed     Text format     Abstract available


  312. LEE J, Jeong SH, Park SM, Sohn EH, et al
    Anti-aquaporin-4 antibody-positive dorsal midbrain syndrome.
    Mult Scler. 2015;21:477-80.
    PubMed     Text format     Abstract available


  313. VISWANATHAN S
    Wasted tongue in neuromyelitis optica spectrum disorders due to hypoglossal nerve involvement.
    Mult Scler. 2015;21:488-91.
    PubMed     Text format     Abstract available


    March 2015
  314. ROBERG BL, Bruce JM
    Reconsidering outdoor temperature and cognition in multiple sclerosis.
    Mult Scler. 2015 Mar 3. pii: 1352458515575172.
    PubMed     Text format     Abstract available


    January 2015
  315. HAUSER SL
    The Charcot Lecture | beating MS: a story of B cells, with twists and turns.
    Mult Scler. 2015;21:8-21.
    PubMed     Text format     Abstract available


  316. VAN SCHEPENDOM J, D'hooghe MB, Cleynhens K, D'hooge M, et al
    Reduced information processing speed as primum movens for cognitive decline in MS.
    Mult Scler. 2015;21:83-91.
    PubMed     Text format     Abstract available


  317. NILSAGARD Y, Gunn H, Freeman J, Hoang P, et al
    Falls in people with MS--an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States.
    Mult Scler. 2015;21:92-100.
    PubMed     Text format     Abstract available


    August 2014
  318. AKHTAR S, Alroughani R, Al-Shammari A, Al-Abkal J, et al
    Month of birth and risk of multiple sclerosis in Kuwait: A population-based registry study.
    Mult Scler. 2014 Aug 4. pii: 1352458514541578.
    PubMed     Text format     Abstract available


    July 2014
  319. FRNDAK SE, Kordovski VM, Cookfair D, Rodgers JD, et al
    Disclosure of disease status among employed multiple sclerosis patients: Association with negative work events and accommodations.
    Mult Scler. 2014 Jul 28. pii: 1352458514540971.
    PubMed     Text format     Abstract available


  320. BOSMA L, Sonder J, Kragt J, Polman C, et al
    Detecting clinically-relevant changes in progressive multiple sclerosis.
    Mult Scler. 2014 Jul 10. pii: 1352458514540969.
    PubMed     Text format     Abstract available


    June 2014
  321. SCHIPPLING S, Balk L, Costello F, Albrecht P, et al
    Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.
    Mult Scler. 2014 Jun 16. pii: 1352458514538110.
    PubMed     Text format     Abstract available


  322. KRYSKO KM, Ivers NM, Young J, O'Connor P, et al
    Identifying individuals with multiple sclerosis in an electronic medical record.
    Mult Scler. 2014 Jun 12. pii: 1352458514538334.
    PubMed     Text format     Abstract available


    May 2014
  323. ROTONDI M, Bergamaschi R, Chiovato L
    Disease modifying therapies in multiple sclerosis: Could a baseline thyroid check-up drive the therapeutic choice between interferon-beta and glatiramer acetate?
    Mult Scler. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: